Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer-Reference-Cited by-同舟云学术

Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer

Published:2001-10 Issue:10 Volume:2 Page:962-970
ISSN:1529-2908
Container-title:Nature Immunology
language:en
Short-container-title:Nat Immunol

Author:

Stanislawski Thomas,Voss Ralf-Holger,Lotz Carina,Sadovnikova Elena,Willemsen Ralph A.,Kuball Jürgen,Ruppert Thomas,Bolhuis Reinder L. H.,Melief Cornelius J.,Huber Christoph,Stauss Hans J.,Theobald Matthias

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy

Link

http://www.nature.com/articles/ni1001-962.pdf

Reference44 articles.

1. Rosenberg, S. A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10, 281–287 (1999).

2. Hanson, H. L. et al. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity 13, 265–276 (2000).

3. Theobald, M., Biggs, J., Dittmer, D., Levine, A. J. & Sherman, L. A. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA 92, 11993–11997 (1995).

4. Vonderheide, R. H., Hahn, W. C., Schultze, J. L. & Nadler, L. M. The telomerase catalytic subunit is a widely expressed tumor associated antigen recognized by cytotoxic T lymphocytes. Immunity 10, 673–679 (1999).

5. Minev, B. et al. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc. Natl. Acad. Sci. USA 97, 4796–4801 (2000).

Cited by 326 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting MDM2 in malignancies is a promising strategy for overcoming resistance to anticancer immunotherapy;Journal of Biomedical Science;2024-01-29

2. T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome;Nature Reviews Drug Discovery;2023-10-27

3. The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells;Molecular Cancer;2023-08-30

4. Role of Metabolism in Adoptive T Cell Therapy: Strategies and Challenges;Antioxidants & Redox Signaling;2022-12-01

5. Cancer Immunotherapy;Holland‐Frei Cancer Medicine;2022-10-21